SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2024 operating results on Wednesday, February 26, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
Conference Call Details
The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID “HCATQ424.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst’s offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.
Health Catalyst Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
ir@healthcatalyst.com
Health Catalyst Media Contact:
Amanda Flanders
Senior Vice President, Marketing and Communications
media@healthcatalyst.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…